BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27920668)

  • 21. Delivery of MicroRNAs by Chitosan Nanoparticles to Functionally Alter Macrophage Cholesterol Efflux in Vitro and in Vivo.
    Nguyen MA; Wyatt H; Susser L; Geoffrion M; Rasheed A; Duchez AC; Cottee ML; Afolayan E; Farah E; Kahiel Z; Côté M; Gadde S; Rayner KJ
    ACS Nano; 2019 Jun; 13(6):6491-6505. PubMed ID: 31125197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement.
    Hoss AG; Labadorf A; Latourelle JC; Kartha VK; Hadzi TC; Gusella JF; MacDonald ME; Chen JF; Akbarian S; Weng Z; Vonsattel JP; Myers RH
    BMC Med Genomics; 2015 Mar; 8():10. PubMed ID: 25889241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-targeted therapeutics for lung cancer treatment.
    Xue J; Yang J; Luo M; Cho WC; Liu X
    Expert Opin Drug Discov; 2017 Feb; 12(2):141-157. PubMed ID: 27866431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shared Molecular Pathways in Glaucoma and Other Neurodegenerative Diseases: Insights from RNA-Seq Analysis and miRNA Regulation for Promising Therapeutic Avenues.
    Vasconcelos CFM; Ribas VT; Petrs-Silva H
    Cells; 2023 Aug; 12(17):. PubMed ID: 37681887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents?
    Angelucci F; Cechova K; Valis M; Kuca K; Zhang B; Hort J
    Front Pharmacol; 2019; 10():665. PubMed ID: 31275145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in miRNA Delivery Systems.
    Dasgupta I; Chatterjee A
    Methods Protoc; 2021 Jan; 4(1):. PubMed ID: 33498244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberration of miRNAs Expression in Leukocytes from Sporadic Amyotrophic Lateral Sclerosis.
    Chen Y; Wei Q; Chen X; Li C; Cao B; Ou R; Hadano S; Shang HF
    Front Mol Neurosci; 2016; 9():69. PubMed ID: 27582688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miRNA and cancer; computational and experimental approaches.
    Tutar Y
    Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene networks in neurodegenerative disorders.
    Recabarren D; Alarcón M
    Life Sci; 2017 Aug; 183():83-97. PubMed ID: 28623007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases.
    Gao J; Wang L; Liu J; Xie F; Su B; Wang X
    Antioxidants (Basel); 2017 Apr; 6(2):. PubMed ID: 28379197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delivery of therapeutic miRNA using polymer-based formulation.
    Ban E; Kwon TH; Kim A
    Drug Deliv Transl Res; 2019 Dec; 9(6):1043-1056. PubMed ID: 31049843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.
    Azam HMH; Rößling RI; Geithe C; Khan MM; Dinter F; Hanack K; Prüß H; Husse B; Roggenbuck D; Schierack P; Rödiger S
    Front Mol Neurosci; 2024; 17():1386735. PubMed ID: 38883980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the treatment of neurodegenerative disorders employing nanoparticles.
    Spuch C; Saida O; Navarro C
    Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):2-18. PubMed ID: 22272933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics.
    Davies KM; Mercer JF; Chen N; Double KL
    Clin Sci (Lond); 2016 Apr; 130(8):565-74. PubMed ID: 26957644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panoramic Visualization of Circulating MicroRNAs Across Neurodegenerative Diseases in Humans.
    Brennan S; Keon M; Liu B; Su Z; Saksena NK
    Mol Neurobiol; 2019 Nov; 56(11):7380-7407. PubMed ID: 31037649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational and in vitro Investigation of miRNA-Gene Regulations in Retinoblastoma Pathogenesis: miRNA Mimics Strategy.
    Venkatesan N; Deepa PR; Khetan V; Krishnakumar S
    Bioinform Biol Insights; 2015; 9():89-101. PubMed ID: 25983556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.